

June 14, 2017



Advaxis to Be Featured on Worldwide Business with kathy ireland®

PRINCETON, N.J.--(BUSINESS WIRE)-- [Advaxis, Inc.](#) (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Advaxis will be featured on [Worldwide Business with kathy ireland®](#) on Sunday, June 18. The 30-minute segment, available on [Youtube](#), includes interviews with Daniel J. O'Connor, President and Chief Executive Officer of Advaxis; Robert Petit, PhD, Chief Scientific Officer; Sara Bonstein, Chief Financial Officer; and Brian Slomovitz, MD, Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Miami Miller School of Medicine.

The episode airs on Fox Business Network as sponsored programming at 5:30 p.m. ET / 2:30 p.m. PT (check your [local listings](#)) and on [Bloomberg International](#) at 10:30 a.m. CT. For more information on Worldwide Business with kathy ireland, visit <http://www.tvwwb.com/>.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a late-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary *Lm* Technology. *Lm* Technology, using bioengineered live attenuated *Listeria monocytogenes* (*Lm*) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead *Lm* Technology™ immunotherapies axalimogene filolisbac and ADXS-DUAL target HPV-associated cancers and are in clinical trials for invasive and metastatic cervical cancer, head and neck cancer and anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA's CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017.

To learn more about Advaxis, visit www.advaxis.com and connect on [Twitter](#), [LinkedIn](#), [Facebook](#), and [YouTube](#).

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis' ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis' proprietary immunotherapies, axalimogene filolisbac and ADXS-DUAL. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis' SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at <http://www.sec.gov>.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law.

You are cautioned not to place undue reliance on any forward-looking statements.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20170614005555/en/>

Company:

[Advaxis, Inc.](#)

Noelle Heber, 609-250-7575

Sr. Director Corporate Communications and Government Affairs

heber@advaxis.com

or

Media Contact:

[JPA Health Communications](#)

David Connolly, 617-657-1301

dconnolly@jpa.com

Source: Advaxis, Inc.